[96a5a0]: / output / chiaCancer / logical / NCT03211741_logical.json

Download this file

576 lines (576 with data), 25.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
{
"info": {
"nct_id": "NCT03211741",
"official_title": "Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema",
"inclusion_criteria": "1. Age ≥ 18 years of either gender\n2. Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed\n3. Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.\n\nIf both eyes are eligible for the study, both eyes can be included in the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5mIU/mL)\n2. Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication\n3. Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab\n4. History of hypersensitivity for bevacizumab.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "1. Age ≥ 18 years of either gender",
"criterions": [
{
"exact_snippets": [
"Age ≥ 18 years"
],
"criterion": "age",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18
}
]
}
},
{
"exact_snippets": [
"either gender"
],
"criterion": "gender",
"requirement_type": "inclusion",
"expected_value": [
"male",
"female"
]
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": [
"Age ≥ 18 years"
],
"criterion": "age",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18
}
]
}
},
{
"exact_snippets": [
"either gender"
],
"criterion": "gender",
"requirement_type": "inclusion",
"expected_value": [
"male",
"female"
]
}
]
}
},
{
"identified_line": {
"line": "2. Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed",
"criterions": [
{
"exact_snippets": [
"Written informed consent must be obtained"
],
"criterion": "informed consent",
"requirement_type": "availability",
"expected_value": true
},
{
"exact_snippets": [
"before any intravitreal injection of bevacizumab is performed"
],
"criterion": "intravitreal injection of bevacizumab",
"requirement_type": "timing",
"expected_value": "before"
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": [
"Written informed consent must be obtained"
],
"criterion": "informed consent",
"requirement_type": "availability",
"expected_value": true
},
{
"exact_snippets": [
"before any intravitreal injection of bevacizumab is performed"
],
"criterion": "intravitreal injection of bevacizumab",
"requirement_type": "timing",
"expected_value": "before"
}
]
}
},
{
"identified_line": {
"line": "3. Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.",
"criterions": [
{
"exact_snippets": [
"Visual impairment predominantly due to abnormal new vessel ingrowth"
],
"criterion": "visual impairment",
"requirement_type": "cause",
"expected_value": "abnormal new vessel ingrowth"
},
{
"exact_snippets": [
"Visual impairment predominantly due to",
"macular edema"
],
"criterion": "visual impairment",
"requirement_type": "cause",
"expected_value": "macular edema"
},
{
"exact_snippets": [
"The presence of fluid"
],
"criterion": "fluid",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"intraretinal"
],
"criterion": "fluid location",
"requirement_type": "location",
"expected_value": "intraretinal"
},
{
"exact_snippets": [
"subretinal"
],
"criterion": "fluid location",
"requirement_type": "location",
"expected_value": "subretinal"
},
{
"exact_snippets": [
"sub-RPE"
],
"criterion": "fluid location",
"requirement_type": "location",
"expected_value": "sub-RPE"
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": [
"Visual impairment predominantly due to abnormal new vessel ingrowth"
],
"criterion": "visual impairment",
"requirement_type": "cause",
"expected_value": "abnormal new vessel ingrowth"
},
{
"exact_snippets": [
"The presence of fluid"
],
"criterion": "fluid",
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": [
"Visual impairment predominantly due to",
"macular edema"
],
"criterion": "visual impairment",
"requirement_type": "cause",
"expected_value": "macular edema"
},
{
"exact_snippets": [
"The presence of fluid"
],
"criterion": "fluid",
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"or_criteria": [
{
"exact_snippets": [
"intraretinal"
],
"criterion": "fluid location",
"requirement_type": "location",
"expected_value": "intraretinal"
},
{
"exact_snippets": [
"subretinal"
],
"criterion": "fluid location",
"requirement_type": "location",
"expected_value": "subretinal"
},
{
"exact_snippets": [
"sub-RPE"
],
"criterion": "fluid location",
"requirement_type": "location",
"expected_value": "sub-RPE"
}
]
}
]
}
},
{
"identified_line": {
"line": "If both eyes are eligible for the study, both eyes can be included in the study.",
"criterions": [
{
"exact_snippets": [
"both eyes are eligible for the study"
],
"criterion": "eyes",
"requirement_type": "eligibility",
"expected_value": true
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": [
"both eyes are eligible for the study"
],
"criterion": "eyes",
"requirement_type": "eligibility",
"expected_value": true
},
"then_criteria": {
"exact_snippets": [
"both eyes are eligible for the study"
],
"criterion": "eyes",
"requirement_type": "inclusion",
"expected_value": true
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": [
"Healthy volunteers allowed"
],
"criterion": "healthy volunteers",
"requirement_type": "participation",
"expected_value": true
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": [
"Healthy volunteers allowed"
],
"criterion": "healthy volunteers",
"requirement_type": "participation",
"expected_value": true
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": [
"minimum age of 18 Years"
],
"criterion": "age",
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": [
"minimum age of 18 Years"
],
"criterion": "age",
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "1. Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5mIU/mL)",
"criterions": [
{
"exact_snippets": [
"Women who are pregnant"
],
"criterion": "pregnancy",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"breastfeeding"
],
"criterion": "breastfeeding",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"positive human chorionic gonadotropin laboratory test (> 5mIU/mL)"
],
"criterion": "human chorionic gonadotropin",
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 5
}
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": [
"Women who are pregnant"
],
"criterion": "pregnancy",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"positive human chorionic gonadotropin laboratory test (> 5mIU/mL)"
],
"criterion": "human chorionic gonadotropin",
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 5
}
]
}
}
]
},
{
"exact_snippets": [
"breastfeeding"
],
"criterion": "breastfeeding",
"requirement_type": "presence",
"expected_value": true
}
]
}
},
{
"identified_line": {
"line": "2. Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication",
"criterions": [
{
"exact_snippets": [
"Women of child bearing potential"
],
"criterion": "child bearing potential",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"must be practicing effective contraception"
],
"criterion": "contraception",
"requirement_type": "practice",
"expected_value": true
},
{
"exact_snippets": [
"implemented during the trial and for at least 28 days following the last dose of study medication"
],
"criterion": "contraception duration",
"requirement_type": "duration",
"expected_value": "during the trial and for at least 28 days following the last dose of study medication"
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": [
"Women of child bearing potential"
],
"criterion": "child bearing potential",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"must be practicing effective contraception"
],
"criterion": "contraception",
"requirement_type": "practice",
"expected_value": true
}
]
},
{
"exact_snippets": [
"implemented during the trial and for at least 28 days following the last dose of study medication"
],
"criterion": "contraception duration",
"requirement_type": "duration",
"expected_value": "during the trial and for at least 28 days following the last dose of study medication"
}
]
}
},
{
"identified_line": {
"line": "3. Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab",
"criterions": [
{
"exact_snippets": [
"Tromboembolic event (CVA or transient ischemic attack, AMI)"
],
"criterion": "tromboembolic event",
"requirement_type": "occurrence",
"expected_value": true
},
{
"exact_snippets": [
"less than 3 months prior to the intravitreal injection of bevacizumab"
],
"criterion": "time since tromboembolic event",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 3
}
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": [
"Tromboembolic event (CVA or transient ischemic attack, AMI)"
],
"criterion": "tromboembolic event",
"requirement_type": "occurrence",
"expected_value": true
},
{
"exact_snippets": [
"less than 3 months prior to the intravitreal injection of bevacizumab"
],
"criterion": "time since tromboembolic event",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 3
}
]
}
}
]
}
},
{
"identified_line": {
"line": "4. History of hypersensitivity for bevacizumab.",
"criterions": [
{
"exact_snippets": [
"History of hypersensitivity for bevacizumab"
],
"criterion": "hypersensitivity",
"requirement_type": "history",
"expected_value": "bevacizumab"
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": [
"History of hypersensitivity for bevacizumab"
],
"criterion": "hypersensitivity",
"requirement_type": "history",
"expected_value": "bevacizumab"
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}